Form D · Biotechnology
Nanocan Therapeutics Corp
National Harbor, MD · CIK 0001820532
Offering snapshot reported Feb 18, 2025 · SEC filing
- Reported sold
- $5.06M Offering amount: $6.46M
- Investors reported
- 41 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 30, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 18, 2025 | Initial | $5,059,984 | No comparison | 41 | SEC filing |
| Aug 27, 2020 | Initial | $1,125,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-538540
A portion of the proceeds were satisfied by cancellation of indebtedness.
Preferred Stock can convert to underlying shares of Common Stock.
Source: Form D, filed Feb 18, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric C. Broyles | Director, Executive |
| Dave Krasne | Executive |
| Jacques P. Walker | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
137 National Plz Ste 300
National Harbor, MD, 20745
National Harbor, MD, 20745